Clinical Trials Directory

Trials / Completed

CompletedNCT04042207

Diabeloop for Highly Unstable Type 1 Diabetes

In Adults With Very Unstable Type 1 Diabetes, is the DBLHU Closed-Loop Insulin Delivery System Able to Improve Blood Glycemic Control Compared to Low-Glucose-Predictive-Suspend System: Two-center, Randomized, Open-label Study

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
7 (actual)
Sponsor
Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète · Academic / Other
Sex
All
Age
22 Years
Healthy volunteers
Not accepted

Summary

Feasibility study, comparing experimental treatment (DBLHU closed-loop system) with reference treatment (Low Glucose Predictive Suspend system) in 7 patients going through a series of N-of-1 trials. Each N-of-1 trial consists in a prospectively planned, multiple crossover study in a single individual. Two blocks of two periods of four weeks each (closed loop or open loop) will be conducted. Within each block, the sequence closed loop-open loop or open loop-close loop is randomized. Outcomes will be analyzed on the third and fourth weeks of period. A remote monitoring system managed by specialized nurse on behalf of diabetologist, is provided in closed-loop session. An extension period of 48 weeks with the DBLHU System (closed-loop condition) will be performed at the end of the crossover study phase in real life conditions (without remote monitoring).

Conditions

Interventions

TypeNameDescription
DEVICELow Glucose Predictive Suspend systemconsists of sensor-augmented pump therapy (SAP) / Low Glucose Predictive Suspend system (with predictive low glucose management technology)
DEVICEDBLHU SystemDBLHU system embeds a regulation algorithm to automatically regulate the patient's glycaemia. It takes as input glycaemia value received every 5 minutes from the CGM and patient inputs related to meals and physical activities and it calculates the amount of insulin to be delivered. It sends this information to the pump that automatically delivers this quantity.

Timeline

Start date
2019-09-03
Primary completion
2020-02-27
Completion
2021-03-22
First posted
2019-08-01
Last updated
2021-05-10

Locations

2 sites across 1 country: France

Source: ClinicalTrials.gov record NCT04042207. Inclusion in this directory is not an endorsement.